CommercialCoverageLow impact
08.01.44c, Voretigene Neparvovec-rzyl (Luxturna®)
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Oct 29, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.01.44c for Voretigene Neparvovec-rzyl (Luxturna®) has been reissued with an effective date of October 29, 2025. This is a pharmacy policy update for this gene therapy medication used to treat inherited retinal diseases.
Action Required
By October 29, 2025: Review updated policy 08.01.44c for Luxturna® gene therapy billing requirements. Since this affects a rare specialty medication for inherited retinal diseases, most practices will not need immediate action unless treating these specific conditions. Ophthalmology practices should verify current prior authorization and coverage requirements.